# Arni Blöndal

> Arni Blöndal is a seed investor at Brunnur Ventures (Reykjavík) backing Biotechnology and B2C. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Brunnur Ventures](https://shizune.co/investors/profile/venture-capital-fund-brunnur)
- Location: Reykjavík, Iceland
- Total investments: 7
- Last investment: Aug 2025
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/arnib/

Arni Blöndal is a seed investor at Brunnur Ventures in Reykjavík focused on Biotechnology and B2C. Arni Blöndal - Managing Partner @ Brunnur Ventures

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 29% |
| B2C | 1 | 14% |
| Rental | 1 | 14% |
| Travel | 1 | 14% |
| Medical | 1 | 14% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 29% |
| Pre-Seed | 1 | 14% |
| Series A | 1 | 14% |
| Series B | 1 | 14% |
| Series C | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Iceland | 2 | 29% |
| Japan | 1 | 14% |
| United States | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Axelyf | Axelyf is a biotechnology company that offers RNA medicines through safer and more effective lipid nanoparticle delivery. | $7.4M | Seed | Aug 07, 2025 |  |
| Trip To Japan | Trip to Japan is a travel booking platform that focuses on creating customizable itineraries for travelers. The platform offers a variety of options, including hotels, ryokans, JR Passes, cultural tours, sightseeing, and adventure trips. With a selection of pre-planned and tailored travel packages, Trip to Japan provides easy online booking andfree cancellations. | $150K | Pre-Seed | Jul 01, 2023 |  |
| Standby Deposits | Standby Deposits is a developer of a renting deposit alternative platform for renters. Its platform connects landlords and tenants and eliminates security deposits by allowing renters to rent property based on their rental credit score along with banking integration to transfer rents on time. | $5.3M | Seed | Apr 19, 2023 |  |
| Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M | Series C | May 04, 2021 |  |
| Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $18.1M | Series B | Jan 04, 2019 |  |
| Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $23.3M | Series B | Jan 04, 2018 |  |
| Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. |  | Series A | Aug 16, 2016 |  |

7 of 7 investments shown.

## Co-investors
- [Silfurberg](https://shizune.co/investors/profile/silfurberg) — VC Fund, 3 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 2 deals together
- [Hyfinity Investments](https://shizune.co/investors/profile/hyfinity-investments) — VC Fund, 2 deals together
- [Nan Fung Life Sciences](https://shizune.co/investors/profile/nan-fung-life-sciences) — VC Fund, 2 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 2 deals together
- [Pivotal bioVenture Partners](https://shizune.co/investors/profile/pivotal-bioventure-partners) — VC Fund, 2 deals together

## About Brunnur Ventures

VC Fund · Reykjavík, Iceland

Brunnur Ventures invests in entities in Iceland and has the ability to invest abroad as a part of the expansion of its portfolio companies internationally. The venture firm does not have a specific industry focus. However, it investments in companies that show great growth potential in specific industry sectors. Brunnur Ventures is the GeneralPartner of Brunnur Venture Capital Fund a USD 40M fund.

4 contacts available at Brunnur Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Arni Blöndal | Managing Partner | https://shizune.co/investors/profile/arni-blondal |
| Sigurdur Arnljotsson | Founding Partner | https://shizune.co/investors/profile/sigurdur-arnljotsson |
| Kjartan Olafsson | Venture Partner | https://shizune.co/investors/profile/kjartan-olafsson |
| Margret Ormslev Asgeirsdottir | Partner | https://shizune.co/investors/profile/margret-ormslev-asgeirsdottir |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Arni Blöndal invest in?

Arni Blöndal invests primarily in Biotechnology, B2C and Rental startups, most often at Seed and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in Iceland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Arni Blöndal last invest?

The most recent investment recorded for Arni Blöndal closed in Aug 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co